Latest Trial Data Shows Potential of BAN2401 in Preventing Cognitive Decline in Early Alzheimer’s

Latest Trial Data Shows Potential of BAN2401 in Preventing Cognitive Decline in Early Alzheimer’s
The latest data from a Phase 2 trial (study 201) demonstrates that BAN2401 can slow cognitive decline, providing additional evidence of its potential as a disease-modifying therapy for Alzheimer's disease, according to Eisai and Biogen, which are jointly developing the investigative therapy. BAN2401 is an engineered antibody designed to specifically bind and neutralize toxic amyloid aggregates, which are well-known contributors of the neurodegenerative process in Alzheimer’s disease. The Phase 2 (study 201) trial (NCT01767311) enrolled 856 patients with early Alzheimer’s disease who had amyloid protein accumulation in the brain. Participants were randomly assigned to receive one of five treatment regimens with the investigative antibody — 2.5 mg, 5 mg, or 10 mg per kg body weight once every two weeks; 5 or 10 mg per kg body weight once a month; or a placebo. The results, announced by Eisai and Biogen, revealed that patients treated with the 10 mg/kg every two weeks regimen for 18 months — the highest tested dose of BAN2401 — had a 30% slower cognitive decline compared to placebo-treated patients. This positive effect, determined by the Alzheimer's Disease Composite Score (ADCOMS), was first noted as early as six months into treatment. Evaluation with the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and the Clinical Dementia Rating Scale–Sum of Boxes
Subscribe or to access all post and page content.


    • Alice Melão says:

      Dear Leonard,
      This drug is still under investigation and has not yet been approved for use in clinical practice by the competent regulatory agencies.
      We will keep providing information on the progress of this potential treatment as additional updates are released by BAN2401’s developers.

  1. Brenda Theus says:

    Anavex 2-73 presented at the AAIC this month shows very promising data. Stop decline and reversed memory loss in some patients. Also showed improvement in insomnia. No adverse side-effects in 57-week study.

  2. Ed Benhoff says:

    Is there any indication as to when BAN2401 might go to trials and, if so where? I’m in the Cleveland area and my wife needs something SOON. Thank you

  3. Linda McConville says:

    My partner needs BAN 2401… Vanderbilt has trials but they are closed… please let us know when open again… who do we contact?? thanks

  4. Arthur Bollon says:

    VITRUVIAN BioMedical Inc ( is developing an Alzheimer’s Disease Vaccine which has the potential to optimize prevention and treatment. The vaccine called YM7555 inhibits both ABeta and TAU accumulation. All Alzheimer’s Disease patients have accumulation of both proteins. One can accumulate ABeta and not get Alzheimer’s Disease. VITRUVIAN also has vaccine YM3711 which targets ABeta and could be more efficient than other ABeta strategies. The vaccines were developed by Dr. Yoh Matsumoto from the Tokyo Metropolitan Institute of Medical Sciences and VITRUVIAN has exclusive global rights. Company also developing early stage Alzheimer’s Disease blood test. For information contact Dr. Arthur Bollon, Chairman, Founder and CEO of VITRUVIAN BioMedical at: [email protected].

  5. here says:

    This is really fascinating, You are a very professional blogger.
    I have joined your feed and sit up for looking for extra of your
    excellent post. Also, I have shared your site in my social networks

Leave a Comment

Your email address will not be published. Required fields are marked *